These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
243 related items for PubMed ID: 21328279
1. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Navaneethan SD, Palmer SC, Vecchio M, Craig JC, Elder GJ, Strippoli GF. Cochrane Database Syst Rev; 2011 Feb 16; (2):CD006023. PubMed ID: 21328279 [Abstract] [Full Text] [Related]
2. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ, Strippoli GF. Cochrane Database Syst Rev; 2018 Aug 22; 8(8):CD006023. PubMed ID: 30132304 [Abstract] [Full Text] [Related]
3. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF. Am J Kidney Dis; 2009 Oct 22; 54(4):619-37. PubMed ID: 19692157 [Abstract] [Full Text] [Related]
4. Interventions for metabolic bone disease in children with chronic kidney disease. Hahn D, Hodson EM, Craig JC. Cochrane Database Syst Rev; 2015 Nov 12; 2015(11):CD008327. PubMed ID: 26561037 [Abstract] [Full Text] [Related]
5. Interventions for bone disease in children with chronic kidney disease. Geary DF, Hodson EM, Craig JC. Cochrane Database Syst Rev; 2010 Jan 20; (1):CD008327. PubMed ID: 20091666 [Abstract] [Full Text] [Related]
9. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA. Sekercioglu N, Angeliki Veroniki A, Thabane L, Busse JW, Akhtar-Danesh N, Iorio A, Cruz Lopes L, Guyatt GH. PLoS One; 2017 Jan 20; 12(3):e0171028. PubMed ID: 28248961 [Abstract] [Full Text] [Related]
11. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Evenepoel P, Selgas R, Caputo F, Foggensteiner L, Heaf JG, Ortiz A, Kelly A, Chasan-Taber S, Duggal A, Fan S. Nephrol Dial Transplant; 2009 Jan 20; 24(1):278-85. PubMed ID: 18820280 [Abstract] [Full Text] [Related]
17. Vitamin D compounds for people with chronic kidney disease requiring dialysis. Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF. Cochrane Database Syst Rev; 2009 Oct 07; (4):CD005633. PubMed ID: 19821349 [Abstract] [Full Text] [Related]
18. Effectiveness and cost-efficacy of phosphate binders in hemodialysis. Brunner-Ziegler S, Fröschl B, Hiebinger C, Zsifkovits J. Ann Nutr Metab; 2011 Oct 07; 58(4):315-9. PubMed ID: 21986491 [Abstract] [Full Text] [Related]
19. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)]. Lorenzo Sellares V, Torregrosa V. Nefrologia; 2008 Oct 07; 28 Suppl 3():67-78. PubMed ID: 19018742 [Abstract] [Full Text] [Related]
20. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients. Ahmadi F, Shamekhi F, Lessan-Pezeshki M, Khatami MR. Saudi J Kidney Dis Transpl; 2012 Sep 07; 23(5):934-8. PubMed ID: 22982903 [Abstract] [Full Text] [Related] Page: [Next] [New Search]